Dynavax Technologies
Emeryville, United States · Founded 1996
- Headquarters
- Emeryville, California
- Employees
- 201–500
- Founded
- 1996
- Business Model
- B2B
About
Dynavax Technologies is a commercial-stage biopharmaceutical company founded in 1996 and headquartered in Emeryville, California, specializing in developing innovative vaccines through Toll-like Receptor (TLR) stimulation to harness the body's innate and adaptive immune responses. Its flagship product HEPLISAV-B is an FDA-approved hepatitis B vaccine for adults, also approved in the EU and UK, and its CpG 1018 adjuvant has been incorporated into multiple COVID-19 vaccines. The company traded publicly (NASDAQ: DVAX) and employed 201-500 people before being acquired by Sanofi in a deal announced December 2025 and completed in 2026 for approximately $2.2 billion, adding Dynavax's adult immunization portfolio to Sanofi's vaccine business.
Summary
Dynavax Technologies is a Biotech company based in Emeryville, United States, founded in 1996.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...